Neoadjuvant therapy preceding prostatectomy for prostate cancer: Rationale and current trials

Expert Review of Anticancer Therapy

Volumn 10, Issue 3, 2010, Pages 439-450

  Sonpavde, Guru ^a,b   Palapattu, Ganesh S ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Section of Medical Oncology   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Androgen deprivation therapy; Biologic agents; Chemotherapy; Neoadjuvant therapy; Prostate cancer

Indexed keywords

ABIRATERONE; ALPHA TOCOPHEROL; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; BEVACIZUMAB; CALCITRIOL; CETUXIMAB; DASATINIB; DOCETAXEL; DUTASTERIDE; ENZASTAURIN; EVEROLIMUS; FINASTERIDE; FLUTAMIDE; GENISTEIN; GOSERELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; IXABEPILONE; METFORMIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROVENGE; RAPAMYCIN; SIMVASTATIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VORINOSTAT;

ADJUVANT CHEMOTHERAPY; ANDROGEN DEPRIVATION THERAPY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COCHRANE LIBRARY; CORRELATION ANALYSIS; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEASIBILITY STUDY; FOLLOW UP; GENE THERAPY; GLEASON SCORE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 77949465177     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.10.17     Document Type: Review

References (75)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Thompson IM Jr, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296, 2329-2335 (2006).
3. Van der Kwast TH, Collette L, Bolla M. Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer. J. Clin. Oncol. 25, 5671-5672 (2007).
4. Van der Kwast TH, Bolla M, Van Poppel H et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J. Clin. Oncol. 25, 4178-4186 (2007).
5. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet 360, 103-106 (2002).
6. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 341, 1781-1788, (1999).
7. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26, 242-245 (2008).
8. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004).
9. Kattan MW, Eastham JA, Stapleton AM et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl Cancer Inst. 90, 766-771 (1998).
10. Symmans WF, Peintinger F, Hatzis C et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25, 4414-4422 (2007).
11. Dowsett M, Smith IE, Ebbs SR et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 99, 167-170 (2007).
12. Soloway MS, Sharifi R, Wajsman Z et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J. Urol. 154, 424-428 (1995).
13. Schulman CC, Debruyne FM, Forster G et al. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur. Urol. 38, 706-713 (2000).
14. Aus G, Abrahamsson PA, Ahlgren G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 90, 561-566 (2002).
15. Gleave ME, Goldenberg SL, Chin JL et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J. Urol. 166, 500-506 (2001).
16. Selli C, Montironi R, Bono A et al. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J. Clin. Pathol. 55, 508-513 (2002).
17. Shelley MD, Kumar S, Wilt T et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat. Rev. 35, 9-17 (2009).
18. Dreicer R, Magi-Galluzzi C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63, 1138-1142 (2004).
19. Magi-Galluzzi C, Zhou M, Reuther AM et al. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 110, 1248-1254 (2007).
20. Febbo PG, Richie JP, George DJ et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin. Cancer Res. 11, 5233-5240 (2005).
21. Shepard DR, Dreicer R, Garcia J et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J. Urol. 181, 1672-1677 (2009).
22. Garzotto M, Myrthue A, Higano CS et al. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol. Oncol. 24, 254-259 (2006).
23. Friedman J, Dunn RL, Wood D et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J. Urol. 179, 911-915 (2008).
24. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295, 1658-1667 (2006).
25. Montgomery B, Lavori P, Garzotto M et al. Veterans Affairs Cooperative Studies Program study 553: chemotherapy after prostatectomy, a Phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology 72, 474-480 (2008).
26. Eigl BJ, Eggener SE, Baybik J et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin. Cancer Res. 11, 4905-4911 (2005).
27. Tang Y, Khan MA, Goloubeva O et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin. Cancer Res. 12, 169-174 (2006).
28. Albain KS, Green SJ, Ravdin PM et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Presented at: 2002 ASCO Annual Meeting 21, 37a (2002) (Abstract 143).
29. Chi KN, Chin JL, Winquist E et al. Multicenter Phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J. Urol. 180, 565-570 (2008).
30. Pettaway CA, Pisters LL, Troncoso P et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J. Clin. Oncol. 18, 1050-1057 (2000).
31. Konety BR, Eastham JA, Reuter VE et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a Phase I/II study. J. Urol. 171, 709-713 (2004).
32. Hussain M, Smith DC, El-Rayes BF et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 61, 774-780 (2003).
33. Clark PE, Peereboom DM, Dreicer R et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57, 281-285 (2001).
34. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731-1740 (2004).
35. Mostaghel EA, Page ST, Lin DW et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67, 5033-5041 (2007).
36. Mostaghel E, Geng L, Coleman R et al. Variability in the androgen response of prostate epithelium to 5a-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res. 70, 1286-1295 (2010).
37. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742-3748 (2009).
38. Vuky J, Porter C, Isacson C et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 115, 784-791 (2009).
39. Canil CM, Moore MJ, Winquist E et al. Randomized Phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 23, 455-460 (2005).
40. Salzberg M, Rochlitz C, Morant R et al. An open-label, noncomparative Phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie 30, 355-360 (2007).
41. Pietras K, Ostman A, Sjoquist M et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61, 2929-2934 (2001).
42. Febbo PG, Thorner A, Rubin MA et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin. Cancer Res. 12, 152-158 (2006).
43. Mathew P, Pisters LL, Wood CG et al. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J. Urol. 181, 81-87 (2009).
44. Mathew P, Thall PF, Bucana CD et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin. Cancer Res. 13, 5816-5824 (2007).
45. Oh WK FP, Richie JP et al. A Phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. J. Clin. Oncol. 27, 15s (2009) (Abstract 5060).
46. Sonpavde G, Periman PO, Bernold D et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. 21(2), 319-324 (2009).
47. Dror Michaelson M, Regan MM, Oh WK et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann. Oncol. 20, 913-920 (2009).
48. Efstathiou E, Troncoso P, Wen S et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin. Cancer Res. 13, 1224-1231 (2007).
49. Dahut WL, Gulley JL, Arlen PM et al. Randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol. 22, 2532-2539 (2004).
50. Garcia JA, Klein EA, Magi-Galluzzi C et al. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin. Cancer Res. 14, 3052-3059 (2008).
51. Dreicer R, Klein EA, Elson P et al. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol. Oncol. 23, 82-86 (2005).
52. Small EJ, Tchekmedyian NS, Rini BI et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13, 1810-1815 (2007).
53. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094 (2006).
54. Schellhammer PF HC, Berger ER et al. A randomized, double-blind, placebo-controlled, multi-center, Phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). Presented at: American Urological Association Annual Meeting. Chicago, IL, USA 28 April 2009 (Abstract 4).
55. Ayala G, Yan J, Li R et al. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin. Cancer Res. 14, 7511-7518 (2008).
56. Sonpavde G, Frolov A, Macdonell V et al. Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP). J. Clin. Oncol. 27, 15s (2009) (Abstract 5127).
57. Swami S, Krishnan AV, Moreno J et al. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int. J. Cancer 124, 2050-2059 (2009).
58. Chi KN, Eisenhauer E, Fazli L et al. A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2́-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl Cancer Inst. 97, 1287-1296 (2005).
59. Chi KN, Hotte SJ, Yu E et al. Mature results of a randomized Phase II study of OGX-011 in combination with docetaxel/ prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 27, 15s (2009) (Abstract 5012).
60. Sooriakumaran P, Macanas-Pirard P, Bucca G et al. A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer. Cancer Genomics Proteomics 6(2), 93-99 (2009).
61. Antonarakis ES, Heath EI, Walczak JR et al. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J. Clin. Oncol. 27(30), 4986-4993 (2009).
62. Pisters LL, Pettaway CA, Troncoso P et al. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin. Cancer Res. 10, 2587-2593 (2004).
63. Trudel S, Trachtenberg J, Toi A et al. A Phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther. 10, 755-763 (2003).
64. Belldegrun A, Tso CL, Zisman A et al. Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology. Hum. Gene Ther. 12, 883-892 (2001).
65. Naruishi K, Timme TL, Kusaka N et al. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther. 13, 658-663 (2006).
66. Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J. Clin. Oncol. 26, 778-785 (2008).
67. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003).
68. Sonpavde G, Goldman BH, Speights VO et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115, 4104-4109 (2009).
69. Wang L, Hricak H, Kattan MW et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238, 597-603 (2006).
70. Esserman LJ. Perou C, Cheang M et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). J. Clin. Oncol. 27, 18s (2009) (Abstract LBA515).
71. Donat SM, Shabsigh A, Savage C et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur. Urol. 55(1), 177-185 (2008).
72. Pilepich MV, Krall JM, al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45, 616-623 (1995).
73. Kelly WK, Halabi S, Elfiky A et al. Multicenter Phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer 113, 3137-3145 (2008).
74. Ryan CJ, Zelefsky MJ, Heller G et al. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. Urology 64, 90-94 (2004).
75. Mohsin SK, Weiss HL, Gutierrez MC et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J. Clin. Oncol. 23, 2460-2468 (2005).